Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets

Author(s): Guilherme Felipe dos Santos Fernandes, Daniela Hartmann Jornada, Paula Carolina de Souza, Chung Man Chin, Fernando Rogério Pavan, Jean Leandro dos Santos

Journal Name: Current Medicinal Chemistry

Volume 22 , Issue 27 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Tuberculosis (TB) is an infectious disease caused by bacterium of the Mycobacterium genus, mainly by Mycobacterium tuberculosis (MTB). The World Health Organization aims to substantially reduce the number of cases in the coming years; however, the increased number of multidrug-resistant (MDR) and extremely drug-resistant (XDR) forms of the bacterium and the lack of treatment for latent tuberculosis are challenges to be overcome. In this review, we have identified the most potent compounds described in the literature during recent years with MIC values < 7 µM, low toxicity and a high selective index. In addition, emerging targets in MTB are presented to provide new perspectives for the discovery of new antitubercular drugs. This review aims to summarize the current advances in and promote insights into antitubercular drug discovery.

Keywords: Antitubercular drugs, drug discovery, Mycobacterium tuberculosis, resistant tuberculosis, tuberculosis, tuberculosis targets.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 16 September, 2015
Page: [3133 - 3161]
Pages: 29
DOI: 10.2174/0929867322666150818103836
Price: $65

Article Metrics

PDF: 53
PRC: 1